Jagsonpal Pharmaceuticals has allotted 56,571 equity shares under ESOP on 18 November 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,34,49,398 (constituting of 6,67,24,699 equity shares of Rs. 2/- each) to Rs. 13,35,62,540 (constituting of 6,67,81,270 equity shares of Rs. 2/- each).Powered by Capital Market - Live News

Net profit of Jagsonpal Pharmaceuticals rose 9.69% to Rs 12.57 crore in the quarter ended September 2025 as against Rs 11.46 crore during the previous quarter ended September 2024. Sales declined 0.29% to Rs 74.47 crore in the quarter ended September 2025 as against Rs 74.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales74.4774.69 0 OPM %22.0821.81 - PBDT19.2017.71 8 PBT16.8115.37 9 NP12.5711.46 10 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals has allotted 66,000 equity shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employees of the Company, upon exercise of vested options. These shares shall rank Pari-passu with the existing equity shares of the Company, in all respects. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,31,30,508 (constituting of 6,65,65,254 equity shares of Rs. 2/- each) to Rs. 13,32,62,508 (constituting of 6,66,31,254 equity shares of Rs. 2/- each).Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals announced that the 45th Annual General Meeting(AGM) of the company will be held on 24 September 2025.Powered by Capital Market - Live News